Compare ResMed Inc. (RMD) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Under Armour Inc Class A — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.73B), while Under Armour Inc Class A trades at $5.07 (market cap $2.08B). The key difference: ResMed Inc. is far larger — about 15.3× Under Armour Inc Class A's market cap, and ResMed Inc. pays a 1.2% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| RMD | UAA | |
|---|---|---|
Market Cap | $31.73B | $2.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $283.28 | $8.14 |
52-Week Low | $182.82 | $4.17 |
Enterprise Value | $31.08B | $3.06B |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% on the day, with a bearish technical signal and key support at $218. The company reported strong Q4 2026 results, beating EPS estimates at $2.95, and maintains robust profitability with a 26.94% net income margin. Revenue growth remains solid, reaching $5.15B in 2025, though weak 2027 sales guidance has pressured the stock. A dividend of $0.66 is scheduled for payment in September 2026.
Outlook is mixed: strong fundamentals and a consensus price target of $235.70 suggest upside, but bearish technicals and investor lawsuits pose near-term risks. The stock offers value with a P/E of 21.19, yet competitive and regulatory challenges require monitoring for sustained growth.
Under Armour (UAA) trades at $5.06, down 3.62% on the day, reflecting persistent investor concerns. The stock is technically bearish, with moving averages signaling a downtrend. Fundamentally, the company reported a net loss of $201.27 million in 2025, with revenue declining to $5.16 billion. Recent news highlights a reduced revenue outlook for fiscal 2027, though cost discipline aims to preserve profitability.
The outlook remains challenging due to weak North American demand and falling revenue projections. Analyst consensus is a 'Hold' with a $6.67 price target, indicating cautious optimism for margin recovery. Key risks include sustained sales weakness and high debt levels. The stock offers potential upside if margin improvements materialize, but near-term headwinds dominate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
